Impact of neoadjuvant androgen ablation and other factors on late toxicity following external beam prostate radiation
M.C Liu(BC Cancer Agency), J. Wu, Eric Berthelet(University of British Columbia), Tom Pickles, Mira Keyes(BC Cancer Agency), Howard Pai(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Alex Agranovich(BC Cancer Agency), Gillian Duncan(University of British Columbia), W. Kwan, Scott Tyldesley(BC Cancer Agency), James Morris(BC Cancer Agency)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2002
Cited by 5
Related Papers
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial
|The Lancet Oncology|2019|459
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319
cAMP regulates morphogenesis in the fungal pathogen Ustilago maydis.
|Genes & Development|1994|303